Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in ...

Background Treatment options for patients suffering from progressive forms of multiple sclerosis (MS) remain inadequate. Mast cells actively participate in the pathogenesis of MS, in part because ...

Subcutaneous ocrelizumab (SC OCR) was found to be safe for patients with relapsing and primary progressive multiple sclerosis ...

Published extended data from the phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting MS in the peer reviewed journal, Neurology® Neuroimmunology & Neuroinflammation, an official ...

A climate activist said today that she will “boldly” make a challenge for the House of Assembly seat won for the Progressive Labour Party by Wayne Caines in 2020. Noelle Young will stand as an ...

Age is a major modifier of inflammatory CSF signatures in MS. This finding identifies novel biomarker candidates and potential therapeutic targets.

Rese-cel, previously called CABA-201, is a CAR T-cell therapy that's designed to treat MS by depleting B-cells.

The company is testing a fully human anti-CD3 monoclonal antibody, foralumab, in secondary progressive multiple sclerosis [SPMS] and Alzheimer’s disease [AD]. Trial results from a randomized ...

An independent candidate running in the General Election next month was inspired to enter politics in part by her late ...

The Regional Independent Group is made up of Michael Lowry, Seán Canney, Kevin 'Boxer' Moran, Noel Grealish, Marian Harkin, ...